Amneal Pharmaceuticals LLC

Saol International Limited

Manuel Weinheimer

Sharon Hamm

David Penake

Leonard O'Mahony

John Devane

Wolfgang Mohr

Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure to baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.

Baclofen formulations and methods of minimizing patient exposure to metabolite variations

Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) ('baclofen') and its pharmaceutically acceptable salts.

Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

Baclofen formulations, including formulations that minimize variability between doses, that minimize variation in patient exposure baclofen metabolites, and are bioequivalent in regards to baclofen versus M1 metabolite ratios of baclofen tablets.

Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use.

Growing community of inventors

Neuenburg am Rhein, Germany

Manuel Weinheimer